Comparative effectiveness of alternative clinical pathways for primary hip and knee joint replacement patients: A pragmatic randomized, controlled trial

Osteoarthritis and Cartilage

Volumn 20, Issue 10, 2012, Pages 1086-1094

  Gooch, K ^a,b   Marshall, D A ^b,c,d   Faris, P D ^b   Khong, H ^b   Wasylak, T ^e   Pearce, T ^f   Johnston, D W C ^g   Arnett, G ^g   Hibbert, J ^b   Beaupre, L A ^g   Zernicke, R F ^h   Frank, C ^b,d  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF CALGARY   (Canada)

^c Chaires de recherche du Canada   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e ALBERTA HEALTH SERVICES   (Canada)

^f Red Deer Regional Hospital Centre   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Alternative clinical pathway; Comparative effectiveness; Degenerative joint disorder; Joint replacement

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL PATHWAY; CONTROLLED STUDY; FEMALE; HEALTH CARE FACILITY; HEALTH CARE QUALITY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEW CLINICAL PATHWAY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

AGED; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CRITICAL PATHWAYS; FEMALE; HEALTH STATUS; HUMANS; MALE; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TREATMENT OUTCOME;

EID: 84865286777     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2012.06.017     Document Type: Article

References (42)

1. Teutsch S.M., Berger M.L., Weinstein M.C. Comparative effectiveness: asking the right questions, choosing the right method. Health Aff (Millwood) 2005, 24(1):128-132.
2. Tunis S.R., Stryer D.B., Clancy C.M. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003, 290(12):1624-1632.
3. Wilensky G.R. Developing a center for comparative effectiveness information. Health Aff (Millwood) 2006, 25(6):w572-w585.
4. Sox H.C. Defining comparative effectiveness research: the importance of getting it right. Med Care 2010, 48(6):S7-S8.
5. Public Health Agency of Canada Life with Arthritis in Canada: A Personal and Public Health Challenge 2010, Canada;, p. 107-109.
6. Healthcare Cost and Utilization Project HCUP Facts and Figures: Statistics on Hospital-based Care in the United States 2009, pp. 3-5 United States.
7. Barbieri A., Vanhaecht K., Van H.P., Sermeus W., Faggiano F., Marchisio S., et al. Effects of clinical pathways in the joint replacement: a meta-analysis. BMC Med 2009, 7:32.
8. Campbell H., Hotchkiss R., Bradshaw N., Porteous M. Integrated care pathways. BMJ 1998, 316(7125):133-137.
9. Dowsey M.M., Kilgour M.L., Santamaria N.M., Choong P.F. Clinical pathways in hip and knee arthroplasty: a prospective randomised controlled study. Med J Aust 1999, 170(2):59-62.
10. Healy W.L., Ayers M.E., Iorio R., Patch D.A., Appleby D., Pfeifer B.A. Impact of a clinical pathway and implant standardization on total hip arthroplasty: a clinical and economic study of short-term patient outcome. J Arthroplasty 1998, 13(3):266-276.
11. Panella M., Marchisio S., Di S.F. Reducing clinical variations with clinical pathways: do pathways work?. Int J Qual Health Care 2003, 15(6):509-521.
12. Pearson S., Moraw I., Maddern G.J. Clinical pathway management of total knee arthroplasty: a retrospective comparative study. Aust N Z J Surg 2000, 70(5):351-354.
13. Pennington J.M., Jones D.P., McIntyre S. Clinical pathways in total knee arthroplasty: a New Zealand experience. J Orthop Surg (Hong Kong) 2003, 11(2):166-173.
14. Vanhaecht K., Sermeus W., Tuerlinckx G., Witters I., Vandenneucker H., Bellemans J. Development of a clinical pathway for total knee arthroplasty and the effect on length of stay and in-hospital functional outcome. Acta Orthop Belg 2005, 71(4):439-444.
15. Vanhaecht K., Bollmann M., Bower K., Gallagher C., Gardini A., Guezo J., et al. Prevalence and use of clinical pathways in 23 countries - an international survey by the European Pathway Association. Int J Care Pathways 2006, 10:28-34.
16. Gooch K.L., Smith D., Wasylak T., Faris P.D., Marshall D.A., Khong H., et al. The Alberta hip and knee replacement project: a model for health technology assessment based on comparative effectiveness of clinical pathways. Int J Technol Assess Health Care 2009, 25(2):113-123.
17. Angst F., Aeschlimann A., Steiner W., Stucki G. Responsiveness of the WOMAC osteoarthritis index as compared with the SF-36 in patients with osteoarthritis of the legs undergoing a comprehensive rehabilitation intervention. Ann Rheum Dis 2001, 60(9):834-840.
18. Alberta Bone and Joint Health Institute Alberta Hip and Knee Replacement Pilot Project 2007, Scientific Evaluation Report, Calgary, Alberta.
19. Alberta Health & Wellness Alberta Hip and Knee Replacement Project Evaluation Report 2006.
20. Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., Stitt L.W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988, 15(12):1833-1840.
21. Ware J.E., Kosinski M., Gandek B. SF-36 Health Survey Manual and Interpretation Guide 2005, Quality Metric Inc., Lincoln.
22. Von K.M., Wagner E.H., Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992, 45(2):197-203.
23. American Society of Anesthesiologists ASA Physical Status Classification System 13-6-2011.
24. Canadian Patient Safety Institute Canadian Disclosure Guidelines 2008, Canadian Patient Safety Institute, Edmonton, Alberta.
25. Bellamy N. WOMAC Osteoarthritis Index User Guide. Version VII 2004, Brisbane: Australia.
26. Albert P.S. Tutorial in Biostatistics: longitudinal data analysis (repeated measures) in clinical trials. Stat Med 1999, 18:1707-1732.
27. Mallinckrodt C.H., Sanger T.M., Dube S., DeBrota D.J., Molenberghs G., Carroll R.J., et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry 2003, 53(8):754-760.
28. Chakraborty H., Gu H. A Mixed Model Approach for Intent-to-treat Analysis in Longitudinal Clinical Trials with Missing Data 2009, Research Triangle Park, North Carolina.
29. Wilson N.A., Schneller E.S., Montgomery K., Bozic K.J. Hip and knee implants: current trends and policy considerations. Health Aff (Millwood) 2008, 27(6):1587-1598.
30. Rasanen P., Paavolainen P., Sintonen H., Koivisto A.M., Blom M., Ryynanen O.P., et al. Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs. Acta Orthop 2007, 78(1):108-115.
31. Goldsmith C.H., Boers M., Bombardier C., Tugwell P. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol 1993, 20(3):561-565.
32. Quintana J.M., Escobar A., Bilbao A., Arostegui I., Lafuente I., Vidaurreta I. Responsiveness and clinically important differences for the WOMAC and SF-36 after hip joint replacement. Osteoarthritis Cartilage 2005, 13(12):1076-1083.
33. Escobar A., Quintana J.M., Bilbao A., Arostegui I., Lafuente I., Vidaurreta I. Responsiveness and clinically important differences for the WOMAC and SF-36 after total knee replacement. Osteoarthritis Cartilage 2007, 15(3):273-280.
34. Aynardi M., Pulido L., Parvizi J., Sharkey P.F., Rothman R.H. Early mortality after modern total hip arthroplasty. Clin Orthop Relat Res 2009, 467(1):213-218.
35. Howie C., Hughes H., Watts A.C. Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. J Bone Joint Surg Br 2005, 87(12):1675-1680.
36. Khatod M., Inacio M., Paxton E.W., Bini S.A., Namba R.S., Burchette R.J., et al. Knee replacement: epidemiology, outcomes, and trends in Southern California: 17,080 replacements from 1995 through 2004. Acta Orthop 2008, 79(6):812-819.
37. Liu S.S., Della Valle A.G., Besculides M.C., Gaber L.K., Memtsoudis S.G. Trends in mortality, complications, and demographics for primary hip arthroplasty in the United States. Int Orthop 2009, 33(3):643-651.
38. Memtsoudis S.G., Gonzalez D.V., Besculides M.C., Gaber L., Sculco T.P. In-hospital complications and mortality of unilateral, bilateral, and revision TKA: based on an estimate of 4,159,661 discharges. Clin Orthop Relat Res 2008, 466(11):2617-2627.
39. Pulido L., Parvizi J., Macgibeny M., Sharkey P.F., Purtill J.J., Rothman R.H., et al. In hospital complications after total joint arthroplasty. J Arthroplasty 2008, 23(6 Suppl 1):139-145.
40. Zhan C., Kaczmarek R., Loyo-Berrios N., Sangl J., Bright R.A. Incidence and short-term outcomes of primary and revision hip replacement in the United States. J Bone Joint Surg Am 2007, 89(3):526-533.
41. Canadian Institute of Health Information Canadian Joint Replacement Registry (CJRR) 2007 Annual Report 2007, Hip and Knee Replacements in Canada.
42. Medical Research Council A Framework for Development and Evaluation of RCTs for Complex Interventions to Improve Health 2000.